Sarepta Therapeutics (SRPT) Stock: Investors Brace for Pivotal Monday Data Release

TLDR Sarepta Therapeutics announces January 26 release of 3-year EMBARK study data for Elevidys gene therapy at 8:30 am ET Stock dropped 3% to $21.13 Friday but surged 5% after hours to $22.20 on the announcement FDA restricted Elevidys to ambulatory patients only after acute liver failure deaths in non-ambulatory patients Company reported $898.7 million [...]

The post Sarepta Therapeutics (SRPT) Stock: Investors Brace for Pivotal Monday Data Release appeared first on Blockonomi.